BNET Industries
Market Cap:$295.2M
Last Fiscal Year Sales:$91.8M
- Public
Dow Jones Description
Comet Technologies, Inc. (the "Company" or "Comet") is a "blank check" company which has been seeking to locate a business enterprise which it may acquire, merge or reorganize with, or become engaged in. The Company has been inactive for several years, and until January, 2004, when it entered into an agreement with Town House Land Limited, discussed below, had not located any specific business enterprise for its involvement, nor had it entered into any arrangement or agreements with respect thereto. Since the completion of the Company's public offering in August 1986, the Company has reviewed and evaluated numerous business ventures for possible acquisition or participation by the Company. To date, the Company has not acquired any business venture or engaged in any active operations. The Company was inactive until January, 2004, when the Company entered into a Stock Exchange Agreement (the "Exchange Agreement") with Town House Land Limited ("Town House"), a company organized in the Hong Kong Special Administrative Region in The People's Republic of China, and the shareholders of Town House, providing for the acquisition of Town House in a reverse acquisition.
Chief Financial Officer
Han XiaoNumber of Employees 1,804
Contact Information
No. 38 Dingxin 3rd Street
Nangang District, Heilongjiang Province
Harbin 150001
213-488-5131
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
China Sky One Nears Approval on Two Diagnostic Tests
-
Gentium loses CEO, board
News & Analysis
Filter by
china sky one medical inc. and finance - All News and Analysis
Nine New Drugs for China Sky One
Seeking Alpha
- 2008-11-13
ChinaBio Today submits: China Sky One Medical, Inc. CSKI has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China...
China Sky One Expands into Injected Drugs
Seeking Alpha
- 2008-10-31
ChinaBio Today submits: China Sky One Medical CSKI received SFDA approval for two new products. Sodium ferulate by injection, a TCM found in the root of Angelica sinensis, is indicated for cardiovascular disease. The drug inhibits the gathering of hematoblasts and stretches blood vessels in order to protect cardiac...
China Sky One Adds Breast Lesion Drug to Product Portfolio
Seeking Alpha
- 2008-10-30
ChinaBio Today submits: China Sky One Medical CSKI has bought a proprietary breast lesion drug from Harbin Medical University for 10 million RMB ($1.5 million). The drug, which China Sky One and Harbin developed jointly, has completed its Phase I trial. In the more than 10,000 patients enrolled in...
China Sky One Starts Production at New Subsidiary
Seeking Alpha
- 2008-10-15
ChinaBio Today submits: China Sky One Medical CSKI announced that production has started at the Peng Lai Jin Chuang company facility. China Sky One finalized the acquisition of Jin Chuang last month, paying $7.1 million in cash and stock to gain control of the company. Jin Chuang...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Han Xiao | Chief Financial Officer |
| Han Xiao-Yan | Principal Financial Officer and Director |
| Wen Chao Zhang | Director of Scientific and Technological Development |
Ms. Han had five years of hygiene and medical media experience before joining TDR. She has been instrumental in developing and marketing TDR’s products and expanding its sales. She serves as a senior marketing manager and administrative manager and has 10 years of financial management experience. In 2004, she was appointed the general manager of TDR, with responsibility for financing, production, quality control and purchasing. In 2003, she was appointed director of Harbin First Bio-Engineering. She received Master of Business Administration at Harbin Industrial University in 2004. Ms. Han Xiao-yan owns 1,406,717 shares, 8.9% of outstanding shares.
| Organization | Position | Status |
|---|---|---|
| China Sky One Medical, Inc. | Chief Financial Officer | Current |
| Organization | Position | Status |
|---|---|---|
| China Sky One Medical, Inc. | Principal Financial Officer and Director | Current |
| Organization | Position | Status |
|---|---|---|
| China Sky One Medical, Inc. | Director of Scientific and Technological Development | Current |
| Volume | 94,173 |
| Shares Outstanding | 16.6M |
| Market Cap | 295.2M |
| Year High | 19.11 |
| Year Low | 10.030 |
| Earnings Per Share | 2.19 |
| P/E Ratio | 8.0913 |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
